Drug Trial Radar · NCT07474636
Efficacy and Safety Study of HS-10542 for IgA Nephropathy
Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Mar 17, 2026
Primary completion
Dec 10, 2027
Study completion Jan 30, 2028
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, parallel, placebo-controlled study and is being conducted to evaluate the efficacy and safety of HS-10542 capsules for primary IgA nephropathy.
Conditions
- IgAN
- Immunoglobulin A Nephropathy (IgAN)
- Glomerular Disease
Interventions
HS-10542 High DoseDrug
Drug: HS-10542 High Dose, QD
HS-10542 Low DoseDrug
Drug: HS-10542 Low Dose, QD
PlaceboDrug
Placebo, QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio to baseline in Urine Protein to Creatinine Ratio (sampled from 24h urine collection)Time frame: Baseline and Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.